Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington's Disease or Tardive Dyskinesia

被引：0
|
作者：
Ayyagari, R. [1 ]
Wilhelm, A. [1 ]
Alexander, J. [1 ]
Chaijale, N. [1 ]
Garcia-Horton, V. [1 ]
Devine, F. [1 ]
Carroll, B. [1 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
来源：
MOVEMENT DISORDERS | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
76
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [41] Treatment Patterns in a Real-World Sample of Patients with Parkinson's Disease and Motor Fluctuations
    Hauser, Robert A.
    Sethi, Kapil
    Klepitskaya, Olga
    Odak, Shardul
    Joshi, Namita
    Kebede, Nehemiah
    Olson, Kurt
    Liang, Grace S.
    Yonan, Chuck
    Serbin, Michael
    ANNALS OF NEUROLOGY, 2021, 90 : S153 - S153
  • [42] deutetrabenazine for the treatment of chorea associated with Huntington's disease
    Gupta, Harshit
    Perkins, Wil
    Stark, Cain
    Kikkeri, Sathya
    Kakazu, Juyeon
    Kaye, Adam
    Kaye, Alan
    HEALTH PSYCHOLOGY RESEARCH, 2022, 10 (05): : 1 - 9
  • [43] RE-KINECT, A REAL-WORLD, PROSPECTIVE TARDIVE DYSKINESIA SCREENING STUDY: AN EVALUATION OF BASELINE CHARACTERISTICS IN OLDER PATIENTS
    Caroff, Stanley
    Cutler, Andrew
    Tanner, Caroline
    Yeomans, Karen
    Lenderking, William
    Shalhoub, Huda
    Chen, Jun
    Anthony, Ericha
    Yonan, Chuck
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2019, 27 (03): : S176 - S179
  • [44] Deutetrabenazine: A Review in Chorea Associated with Huntington’s Disease
    Young-A Heo
    Lesley J. Scott
    Drugs, 2017, 77 : 1857 - 1864
  • [45] Patterns of Improvement with Valbenazine in Patients with Tardive Dyskinesia
    Correll, C.
    Carmack, T.
    Shah, C.
    Lundt, L.
    MOVEMENT DISORDERS, 2021, 36 : S152 - S152
  • [46] Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease
    Heo, Young-A
    Scott, Lesley J.
    DRUGS, 2017, 77 (17) : 1857 - 1864
  • [47] Comparison of Safety and Tolerability of Deutetrabenazine (DTBZ) During Titration and Maintenance in Patients With Tardive Dyskinesia (TD)
    Anderson, K.
    Fernandez, H.
    Barkay, H.
    Wilhelm, A.
    Chaijale, N.
    Send, A.
    Savola, J. M.
    Gordon, M.
    MOVEMENT DISORDERS, 2020, 35 : S30 - S31
  • [48] NMDA receptor co-determines vulnerability to develop dyskinesia in Huntington's Disease and levodopa-induced dyskinesia but not tardive dyskinesia
    Loonen, A. J. M.
    Ivanova, S. A.
    Pechlivanoglou, P.
    Rudikov, E.
    Zhukova, I.
    Al Hadithy, A. F. Y.
    Alifirova, V.
    Brouwers, J. R. B. J.
    Semke, A.
    Wilffert, B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S142 - S142
  • [49] Secukinumab treatment for ankylosing spondylitis and concomitant Huntington's disease: real-world experience
    Gokten, D. Bulut
    Mercan, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (03) : 767 - 767
  • [50] REAL-WORLD HEALTH CARE RESOURCE UTILIZATION AND COSTS OF HUNTINGTON'S DISEASE IN ISRAEL
    Ribalov, R.
    Yaari, A.
    Chodick, G.
    Barer, Y.
    VALUE IN HEALTH, 2020, 23 : S627 - S627
12345